METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Apr 3, 2025
app pub date -
Sep 26, 2024
filing date -
Sep 26, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Methods of using a sodium glucose cotransporter 2 (SGLT2) inhibitor to treat type 1 diabetes, improve cardiovascular health, slow kidney function decline, reduce the risk of cardiovascular death, and reduce the risk of hospitalization for heart failure while minimized adverse events such as diabetic ketoacidosis and severe hypoglycemia are disclosed. In preferred methods, the SGLT2 inhibitor is sotagliflozin. Methods of prescribing and administering sotagliflozin are also disclosed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully